tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Lenz Therapeutics price target raised to $53 from $44 at BofA
PremiumThe FlyLenz Therapeutics price target raised to $53 from $44 at BofA
2M ago
Lenz Therapeutics price target raised to $56 from $48 at H.C. Wainwright
Premium
The Fly
Lenz Therapeutics price target raised to $56 from $48 at H.C. Wainwright
2M ago
Buy Rating for LENZ Therapeutics: Vizz’s Early FDA Approval and Market Differentiation Drive Growth Potential
Premium
Ratings
Buy Rating for LENZ Therapeutics: Vizz’s Early FDA Approval and Market Differentiation Drive Growth Potential
2M ago
LENZ Therapeutics trading halted, news pending
PremiumThe FlyLENZ Therapeutics trading halted, news pending
2M ago
LENZ Therapeutics’ LNZ100 Eye Drop Gains Buy Rating Amid Positive KOL Feedback and Strategic Market Positioning
Premium
Ratings
LENZ Therapeutics’ LNZ100 Eye Drop Gains Buy Rating Amid Positive KOL Feedback and Strategic Market Positioning
2M ago
Lenz Therapeutics price target raised to $49 from $45 at Citi
Premium
The Fly
Lenz Therapeutics price target raised to $49 from $45 at Citi
2M ago
Lenz Therapeutics price target raised to $48 from $38 at H.C. Wainwright
PremiumThe FlyLenz Therapeutics price target raised to $48 from $38 at H.C. Wainwright
2M ago
Lenz Therapeutics, Laboratoires Thea enter license, commercialization agreement
Premium
The Fly
Lenz Therapeutics, Laboratoires Thea enter license, commercialization agreement
3M ago
LENZ Therapeutics Holds 2025 Annual Stockholders Meeting
Premium
Company Announcements
LENZ Therapeutics Holds 2025 Annual Stockholders Meeting
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100